Management of Positive Hepatitis B Surface Antigen (HBsAg)

Interpretation of Positive HBsAg

• A positive HBsAg result indicates active HBV infection, which may be acute or chronic, according to the Centers for Disease Control and Prevention 1, 2
• Chronic HBV infection is confirmed by the persistence of HBsAg for at least 6 months and the absence of IgM antibody to hepatitis B core antigen (IgM anti-HBc), as recommended by the American Association for the Study of Liver Diseases 3
• Patients with positive HBsAg should be considered infectious and capable of transmitting HBV via blood/serum or sexual contact, as stated by the Clinical Gastroenterology and Hepatology 3

Initial Evaluation

• Complete laboratory assessment should include tests for coinfection with other viruses (HIV, HCV, HDV) in high-risk individuals, as recommended by the Centers for Disease Control and Prevention 1
• Evaluation of liver fibrosis is recommended in patients with elevated ALT levels, using liver biopsy or non-invasive transient elastography, as suggested by the Clinical Gastroenterology and Hepatology 3 and the Centers for Disease Control and Prevention 2
• Screening for hepatocellular carcinoma (HCC) should be conducted in all HBsAg-positive persons 20 years and older, including baseline ultrasound, as recommended by the Clinical Gastroenterology and Hepatology 3

Management Algorithm

• For chronic infection, assess disease activity and stage by measuring HBV DNA levels and ALT levels, determining HBeAg status, and assessing liver fibrosis, as recommended by the Clinical Gastroenterology and Hepatology 3 and the Annals of Internal Medicine 4
• Determine treatment eligibility based on HBV DNA levels, ALT elevation, presence of significant fibrosis or cirrhosis, HBeAg status, and age and family history of HCC, as suggested by the Clinical Gastroenterology and Hepatology 3
• First-line treatments include pegylated interferon-α2a, entecavir, and tenofovir, with treatment goals of sustained suppression of HBV replication and remission of liver disease, as recommended by the Annals of Internal Medicine 4

Prevention of Transmission

• Counsel patients on preventing transmission by practicing safe sex, avoiding sharing needles, razors, toothbrushes, covering open wounds, and not donating blood, organs, or tissue, as recommended by the Clinical Gastroenterology and Hepatology 3 and the Centers for Disease Control and Prevention 2
• Screen and vaccinate susceptible household members and sexual contacts, as recommended by the Annals of Internal Medicine 4

Monitoring

• Regular monitoring of liver function tests and HBV DNA levels is necessary, as recommended by the Clinical Gastroenterology and Hepatology 3 and the Annals of Internal Medicine 4
• Surveillance for HCC with ultrasound every 6 months in high-risk patients (cirrhosis, family history of HCC, older age) is recommended, as suggested by the Clinical Gastroenterology and Hepatology 3
• For patients on antiviral therapy, monitor for treatment response and development of resistance, as recommended by the Annals of Internal Medicine 4

Special Considerations

• Patients with chronic HBV should be referred to specialists experienced in managing hepatitis B, as recommended by the Clinical Gastroenterology and Hepatology 3
• Patients requiring immunosuppressive therapy need careful monitoring and possibly antiviral prophylaxis to prevent HBV reactivation, as suggested by the Praxis Medical Insights 5
• HBV DNA levels directly correlate with risk of developing cirrhosis and HCC; levels >10^5 copies/mL significantly increase risk, as stated by the Clinical Gastroenterology and Hepatology 3

Common Pitfalls to Avoid

• Not screening high-risk individuals for HBV coinfections (HIV, HCV, HDV) is a common pitfall, as recommended by the Clinical Gastroenterology and Hepatology 3 and the Annals of Internal Medicine 4
• Missing the opportunity to screen and vaccinate close contacts is another common pitfall, as recommended by the Annals of Internal Medicine 4
• Inadequate monitoring for HCC in high-risk patients is a common pitfall, as suggested by the Clinical Gastroenterology and Hepatology 3
• Not recognizing the risk of HBV reactivation in patients receiving immunosuppressive therapy is a common pitfall, as recommended by the Praxis Medical Insights 5

Management of Positive Hepatitis B Surface Antigen (HBsAg)

Interpretation of a Positive HBsAg Result

• A positive HBsAg test signifies an active hepatitis B virus infection (acute or chronic) that requires comprehensive evaluation to define disease phase, assess liver injury, initiate monitoring, and prevent transmission. 6

Diagnostic Criteria for Acute vs. Chronic Infection

• Acute infection is identified by HBsAg positivity together with IgM anti‑HBc positivity. 7
• Chronic infection is defined by HBsAg persistence for more than 6 months with a negative IgM anti‑HBc result; chronicity is confirmed when HBsAg remains detectable beyond this period, whereas acute infection typically resolves within 6 months. 8

Initial Laboratory Evaluation (Baseline Work‑up)

• Order additional HBV serologic markers—including total and IgM anti‑HBc, anti‑HBs, and HBeAg/anti‑HBe—to characterize infection status. 8
• Perform quantitative HBV DNA testing to gauge viral replication and determine treatment eligibility. 8
• Obtain liver function tests (AST, ALT, alkaline phosphatase, bilirubin, albumin, prothrombin time) to assess hepatic injury. 8
• Include a complete blood count and serum creatinine to evaluate overall health and medication safety. 8
• Screen for coinfections: anti‑HCV, anti‑HDV (if injection‑drug use risk), and anti‑HIV (if high‑risk behavior). 8
• Test for hepatitis A immunity (IgG anti‑HAV), especially in individuals younger than 50 years, to guide vaccination needs. 8

Disease‑Phase Classification and Treatment Consideration

• Chronic hepatitis B requiring treatment is indicated when any of the following are present:
• Inactive carrier state (monitor‑only) is characterized by:

Liver Fibrosis Assessment

• Use non‑invasive transient elastography as the preferred initial method to stage fibrosis.
• Reserve liver biopsy for cases where non‑invasive results are inconclusive or additional histologic information is required. 8

Hepatocellular Carcinoma (HCC) Surveillance

• All HBsAg‑positive persons aged ≥ 20 years should undergo baseline abdominal ultrasound and serum alpha‑fetoprotein (AFP) testing for HCC screening. 8
• High‑risk individuals (e.g., cirrhosis, family history of HCC, older age) require repeat ultrasound (and optionally AFP) every 6 months. 8

Treatment Eligibility and Goals

• Eligibility for antiviral therapy is based on HBV DNA level, ALT elevation, presence of significant fibrosis or cirrhosis, and HBeAg status. 8
• The primary therapeutic objective is sustained suppression of HBV DNA with consequent remission of liver disease. 7

Prevention of Transmission to Close Contacts

• Screen household members and sexual partners for HBsAg, anti‑HBc, and anti‑HBs; vaccinate those lacking immunity (negative for all three markers). 8

Lifestyle Recommendations

• Limit or abstain from alcohol, as consumption accelerates liver injury. 8
• Avoid tobacco use, which is associated with faster disease progression. 8
• Provide hepatitis A vaccination to individuals who are anti‑HAV negative to prevent severe coinfection. 8

Special Situations

• Pregnancy or pre‑conception planning: Newborns of HBV‑infected mothers should receive hepatitis B immune globulin (HBIG) and the first dose of hepatitis B vaccine at birth, followed by the standard three‑dose series. 8